New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
08:13 EDTMYOSMYOS extends agreement for Fortetropin
MYOS announced that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V, or DIL, the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin, the first clinically proven natural myostatin inhibitor. DIL Under the terms of the agreement, DIL will manufacture and supply Fortetropin exclusively for MYOS through the end of 2016 with a significant cost-savings component. The supply relationship maintains the stable, world-class manufacturing and supply of Fortetropin, the primary proprietary ingredient in MYOS' core muscle health bionutrition supplement products. Fortetropin is produced using a proprietary method in accordance with the highest industry standards, incorporating DIL's state of the art High Pressure Pasteurization, or HPP, technology for preserving the high quality freshness of the natural ingredients. Use of the proprietary manufacturing process at DIL's cutting edge facilities ensures the continued efficacy and quality of Fortetropin. The Supply Agreement extension also requires ongoing adherence to the highest levels of product testing.
News For MYOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:12 EDTMYOSMYOS study of Fortetropin mechanism of action shows regulatory effects
MYOS announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.
January 12, 2015
07:42 EDTMYOSOneMedMarket to hold a forum
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use